Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 09-Sep-24 5:00 PM View:  | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 09-Sep-24 | Option Sale | 1,840 | $3.04 | $5,586.61 | (< 1%) 215.15K to 213.31K | |
| 09-Sep-24 5:00 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 09-Sep-24 | Option Exercise | 1,840 | $1.43 | $2,631.20 | < 1% 213.31K to 215.15K | |
| 09-Sep-24 5:00 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 06-Sep-24 | Option Sale | 4,219 | $3.03 | $12,784.40 | (2%) 217.53K to 213.31K | |
| 09-Sep-24 5:00 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 06-Sep-24 | Option Exercise | 4,219 | $1.43 | $6,033.17 | 2% 213.31K to 217.53K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 05-Sep-24 | Option Sale | 40,277 | $3.11 | $125,310.00 | (16%) 253.59K to 213.31K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 05-Sep-24 | Option Exercise | 40,277 | $1.43 | $57,596.10 | 19% 213.31K to 253.59K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 04-Sep-24 | Option Exercise | 10,981 | $1.43 | $15,702.80 | 5% 213.31K to 224.29K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 04-Sep-24 | Option Sale | 10,981 | $3.02 | $33,205.40 | (5%) 224.29K to 213.31K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 03-Sep-24 | Option Sale | 3,863 | $3.02 | $11,677.50 | (2%) 217.18K to 213.31K | |
| 05-Sep-24 4:54 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 03-Sep-24 | Option Exercise | 3,863 | $1.43 | $5,524.09 | 2% 213.31K to 217.18K | |
| 29-Aug-24 4:55 PM View: | Meeker David P Director | Trevi Therapeutics, Inc. (TRVI) | 27-Aug-24 | Option Sale | 4,555 | $2.93 | $13,352.50 | (1%) 357.04K to 352.49K | |
| 29-Aug-24 4:55 PM View: | Meeker David P Director | Trevi Therapeutics, Inc. (TRVI) | 27-Aug-24 | Option Exercise | 4,555 | $1.43 | $6,513.65 | 1% 352.49K to 357.04K | |
| 21-Aug-24 4:00 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 19-Aug-24 | Option Exercise | 16,496 | $1.43 | $23,589.30 | 7% 220.31K to 236.81K | |
| 21-Aug-24 4:00 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 19-Aug-24 | Option Sale | 16,496 | $2.96 | $48,882.60 | (7%) 236.81K to 220.31K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 16-Aug-24 | Option Exercise | 18,660 | $1.43 | $26,683.80 | 8% 220.31K to 238.97K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 16-Aug-24 | Option Sale | 18,660 | $2.76 | $51,440.00 | (8%) 238.97K to 220.31K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 15-Aug-24 | Option Sale | 12,745 | $2.79 | $35,512.70 | (5%) 233.06K to 220.31K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 15-Aug-24 | Option Exercise | 12,745 | $1.43 | $18,225.30 | 6% 220.31K to 233.06K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 14-Aug-24 | Option Exercise | 100 | $1.43 | $143.00 | < 1% 220.31K to 220.41K | |
| 16-Aug-24 4:47 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 14-Aug-24 | Option Sale | 100 | $2.75 | $275.00 | (< 1%) 220.41K to 220.31K | |
| 31-May-24 4:07 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 29-May-24 | Option Exercise | 59,354 | $2.19 | $129,985.00 | 28% 208.45K to 267.8K | |
| 31-May-24 4:07 PM View: | Sciascia Thomas Chief Scientific Officer | Trevi Therapeutics, Inc. (TRVI) | 29-May-24 | Option Sale | 53,368 | $2.55 | $136,110.00 | (20%) 267.8K to 214.43K | |
| 24-May-24 4:12 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 22-May-24 | Option Exercise | 16,043 | $0.51 | $8,197.97 | 39% 41.59K to 57.63K | |
| 24-May-24 4:12 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 22-May-24 | Option Sale | 4,350 | $2.64 | $11,484.90 | (8%) 57.63K to 53.28K | |
| 22-May-24 4:30 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 20-May-24 | Option Exercise | 25,037 | $2.19 | $54,831.00 | 12% 213.31K to 238.35K | |
| 22-May-24 4:30 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 20-May-24 | Option Sale | 25,037 | $2.86 | $71,575.80 | (11%) 238.35K to 213.31K | |
| 14-May-24 4:51 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 10-May-24 | Option Exercise | 4,578 | $2.19 | $10,025.80 | 2% 213.31K to 217.89K | |
| 14-May-24 4:51 PM View: | Good Jennifer L President & CEO Director | Trevi Therapeutics, Inc. (TRVI) | 10-May-24 | Option Sale | 4,578 | $2.90 | $13,276.20 | (2%) 217.89K to 213.31K | |
| 12-Oct-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Oct-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 7% 34.39K to 36.69K | |
| 12-Oct-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Oct-23 | Planned Option Sale | 785 | $2.02 | $1,585.70 | (2%) 36.69K to 35.9K | |
| 13-Sep-23 4:06 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Sep-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 7% 32.81K to 35.1K | |
| 13-Sep-23 4:06 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Sep-23 | Planned Option Sale | 711 | $2.20 | $1,564.20 | (2%) 35.1K to 34.39K | |
| 14-Aug-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Aug-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 7% 31.2K to 33.5K | |
| 14-Aug-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Aug-23 | Planned Option Sale | 682 | $2.36 | $1,609.52 | (2%) 33.5K to 32.81K | |
| 12-Jul-23 4:29 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Jul-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 8% 29.6K to 31.89K | |
| 12-Jul-23 4:29 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Jul-23 | Planned Option Sale | 687 | $2.34 | $1,607.58 | (2%) 31.89K to 31.2K | |
| 21-Jun-23 4:00 PM View: | Simon Farrell Chief Commercial Officer | Trevi Therapeutics, Inc. (TRVI) | 20-Jun-23 | Option Exercise | 6,250 | $0.51 | $3,193.75 | 16% 39.4K to 45.65K | |
| 14-Jun-23 4:28 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 12-Jun-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 8% 27.92K to 30.21K | |
| 14-Jun-23 4:28 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 12-Jun-23 | Planned Option Sale | 610 | $2.64 | $1,610.40 | (2%) 30.21K to 29.6K | |
| 15-May-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-May-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 9% 26.19K to 28.48K | |
| 15-May-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-May-23 | Planned Option Sale | 562 | $2.89 | $1,624.18 | (2%) 28.48K to 27.92K | |
| 12-Apr-23 5:02 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-23 | Option Exercise | 2,292 | $0.51 | $1,171.21 | 9% 24.74K to 27.03K | |
| 12-Apr-23 5:02 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 11-Apr-23 | Planned Option Sale | 840 | $1.84 | $1,544.76 | (3%) 27.03K to 26.19K | |
| 15-Mar-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Mar-23 | Option Exercise | 2,291 | $0.51 | $1,170.70 | 10% 23.34K to 25.63K | |
| 15-Mar-23 4:00 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Mar-23 | Planned Option Sale | 892 | $1.75 | $1,563.85 | (3%) 25.63K to 24.74K | |
| 08-Mar-23 4:00 PM View: | Simon Farrell Chief Commercial Officer | Trevi Therapeutics, Inc. (TRVI) | 07-Mar-23 | Option Exercise | 18,750 | $0.51 | $9,581.25 | 91% 20.65K to 39.4K | |
| 15-Feb-23 4:01 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Feb-23 | Option Exercise | 27,500 | $0.51 | $14,052.50 | 638% 4.31K to 31.81K | |
| 15-Feb-23 4:01 PM View: | Delfini Lisa Chief Financial Officer | Trevi Therapeutics, Inc. (TRVI) | 13-Feb-23 | Planned Option Sale | 8,474 | $2.45 | $20,761.30 | (27%) 31.81K to 23.34K | |
| 06-Jul-22 5:00 PM View: | Tpg Gp A, LLC | Trevi Therapeutics, Inc. (TRVI) | 05-Jul-22 | Sale | 63,569 | $3.11 | $197,827.00 | (2%) 3.89M to 3.82M | |
| 06-Jul-22 5:00 PM View: | Tpg Gp A, LLC | Trevi Therapeutics, Inc. (TRVI) | 01-Jul-22 | Private Sale | 436,431 | $2.86 | $1,246,190.00 | (10%) 4.32M to 3.89M |
